Compare BCAL & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BCAL | TECX |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United States | United States |
| Employees | N/A | 60 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.6M | 549.5M |
| IPO Year | 2020 | N/A |
| Metric | BCAL | TECX |
|---|---|---|
| Price | $20.98 | $31.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $20.67 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 244.8K | 184.8K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 777.27 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.67 | N/A |
| P/E Ratio | $50.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.57 | $14.39 |
| 52 Week High | $21.71 | $39.53 |
| Indicator | BCAL | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 47.87 |
| Support Level | $17.97 | $27.31 |
| Resistance Level | $21.50 | $35.99 |
| Average True Range (ATR) | 0.55 | 2.60 |
| MACD | -0.03 | -0.46 |
| Stochastic Oscillator | 48.84 | 17.76 |
California BanCorp is a relationship-focused community bank offering commercial loan and deposit products, along with other services delivered directly or through strategic alliances, to business and individual customers in its target markets. The Company provides financial products and services to individuals, professionals, and small to medium-sized businesses through its branch and commercial banking offices serving California. Its lending products consist mainly of construction and land development loans, real estate loans, C&I loans, and consumer loans, and it is a Preferred SBA Lender, while its deposit products consist mainly of demand deposit, money market, and certificates of deposit. The Company operates in one reportable segment, commercial banking.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.